<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227551</url>
  </required_header>
  <id_info>
    <org_study_id>VLA-007</org_study_id>
    <nct_id>NCT01227551</nct_id>
  </id_info>
  <brief_title>A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )</brief_title>
  <acronym>CALM</acronym>
  <official_title>A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viralytics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in
      terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via
      immune-related Response Criteria [irRECIST 1.1] (revised Response Evaluation Criteria In
      Solid Tumors [RECIST] 1.1).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, 2-stage, single-arm efficacy and safety study.
      Approximately 63 patients with histologically proven stage IIIc or stage IV melanoma who fail
      to qualify for curative surgery and who bear one or more tumors that are accessible for
      direct injections and at least one measurable lesion by RECIST 1.1 criteria will be
      considered.

      Prospective patients will attend the study center for initial screening within 28 days prior
      to treatment with CVA21. They will have the nature of the study and its procedures and risks
      fully explained. All patients must provide a written informed consent to participate in the
      study.

      The dose of CVA21 for this study is 3 x 108 TCID50 (about 4.5 x 106 TCID50/kg for a 70-kg
      patient) by IT administration. Each patient will receive 4 separate CVA21 administrations in
      the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day
      22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a
      maximum of 10 sets of injections) or until confirmed disease progression or development of
      excessive toxicity.

      Disease status will be assessed by contrast-enhanced computerized tomography (CT) or magnetic
      resonance imaging (MRI) scan and/or direct caliper measurement (and ultrasound assistance, if
      necessary) and categorized by immune-related RECIST 1.1 criteria prior to commencing
      treatment (baseline) and at Days 43, 85, 127 and 169 and 12-weekly intervals thereafter until
      disease progression. At 2 years, intervals can increase to 6 months.

      At 12 weeks post-commencement of treatment (Day 85), if a patient's disease status is classed
      as progressive disease (but without rapid clinical deterioration) the patient may remain on
      the trial for a further 6 weeks, when his/her disease status will be confirmed prior to the
      scheduled treatment. If disease progression is confirmed, the patient will cease treatment
      but will remain on the study and be observed for efficacy and safety until initiation of
      treatment with non-CVA21 anticancer therapies. However, survival will be followed until
      death. If stable disease or better (CR or PR) is observed at this time, the patient will
      continue treatment as per the protocol. Complete and partial responses will be confirmed at
      the next contrast-enhanced CT or MRI scan analysis.

      Patients who have evidence of biologic activity, i.e., tumor inflammatory reaction and/or
      stable disease or better, at 18 weeks (Day 127) are eligible to participate in the extension
      trial in which they will continue to receive IT injections of CVA21 every 3 weeks up to a
      total of 1 year of therapy from the first injection.

      Throughout the trial, immunological responses to the tumor and CVA21 will be monitored.

      After the full CVA21 injection schedule has been completed, patients will be followed at
      12-weekly intervals beginning on Day 169 for a total of 12 months according to the schedule
      for safety assessment and indefinitely for survival. Patients with progressive disease (but
      without rapid clinical deterioration) at 6 months (Day 169) will have a further tumor
      assessment 6 weeks later for confirmation or continuation of observation for duration of
      disease control and all subjects will be followed for survival. Patients who are withdrawn
      from treatment with CVA21 during the treatment phase must also be followed up every 6 weeks
      for 12 weeks for safety and for survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate</measure>
    <time_frame>6 months or more</time_frame>
    <description>Per Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI or calipers: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Durable Response Rate (DRR) = CR + PR.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Intratumoral injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coxsackievirus A21 (CVA21)</intervention_name>
    <description>CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.</description>
    <arm_group_label>Intratumoral injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with histologically proven stage IIIc or stage IV melanoma who fails to
             qualify for curative surgery and who bears one or more tumors that are accessible for
             direct injection

          2. Patient must have had no more than one previous systemic regimen for management of
             melanoma; however, adjuvant chemotherapy administered 6 months or longer before
             entering the trial does not count as a line of treatment

          3. Absence of circulating serum neutralizing antibodies to CVA21 (titer &lt; 1:16)

          4. At least one tumor 0.5 to 10 cm in the longest diameter must be suitable for injection
             and at least one tumor must be equal to or greater than 1 cm and qualified to be a
             target lesion for RECIST 1.1 criteria

          5. Patient must have adequate hematologic, hepatic and renal function, defined as:

               -  Absolute neutrophil count (ANC) &gt; 1.5 x 10^9/L, platelets &gt; 100 x 10^9/L

               -  Bilirubin &lt; 1.5 times the upper limit of normal (ULN), aspartate aminotransferase
                  (AST) &lt; 2.5 x ULN

               -  Serum creatinine &lt; 1.5 x ULN; if &gt; 1.5 x ULN, it must be confirmed that
                  creatinine clearance &gt; 30 mL/minute

          6. Serum lactate dehydrogenase (LDH) levels &lt; or = 1.5 x ULN

          7. Male or female age 18 years or older

          8. Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1

          9. Estimated life expectancy of more than 6 months

         10. Recovered from prior therapy with at least 4 weeks since the last exposure to
             chemotherapy or radiotherapy

         11. Patient is able and willing to provide written informed consent to participate in the
             study

         12. Fertile males and females must agree to the use of an adequate form of contraception,
             e.g., condoms for males. A negative pregnancy test is required in female patients of
             childbearing potential.

        Exclusion Criteria:

          1. Mucosal or ocular primary tumors

          2. Bone metastases

          3. Greater than 3 visceral metastases

          4. Any visceral metastases &gt; 10 cm

          5. Serum anti-CVA21 neutralizing titer of &gt; 1:16 at baseline

          6. Presence of any central nervous system (CNS) tumor that has not been stable for at
             least 3 months off corticosteroids and confirmed by imaging

          7. Tumors to be injected lying in mucosal regions or close to an airway, major blood
             vessel or spinal cord that, in the opinion of the Investigators, could cause occlusion
             into a major vessel in the case of necrosis

          8. Only measurable tumor had prior local radiotherapy without subsequent nodule
             progression

          9. Patient has received chemotherapy within the last 4 weeks prior to first injection

         10. ECOG score greater than 1

         11. Estimated life expectancy of less than 6 months

         12. Pregnancy or breastfeeding

         13. Primary or secondary immunodeficiency, including immunosuppressive disease, and
             immunosuppressive doses of corticosteroids (e.g., prednisolone &gt; 7.5 mg per day) or
             other immunosuppressive medications including cyclosporine, azathioprine, interferons
             within the past 4 weeks prior to screening

         14. Positive serology for human immunodeficiency virus (HIV), hepatitis B or C

         15. Full dose anticoagulation or a history of bleeding diathesis or poorly controlled
             bleeding in the last month prior to screening

         16. Previous splenectomy

         17. Presence of uncontrolled infection

         18. Presence of unstable neurological disease

         19. Any uncontrolled medical condition that, in the opinion of the investigator, is likely
             to place the patient at unacceptable risk during the study or reduce his/her ability
             to complete the study

         20. Participation in another study requiring administration of an investigational drug or
             biological agent within the last 4 weeks prior to screening

         21. Any other medical or psychological condition that would preclude participation in the
             study or compromise ability to give informed consent

         22. Participation in any previous melanoma immunotherapy trial within 1 month prior to
             entry to this trial or any trial of any other investigational agent within the last
             month prior to entry to this trial

         23. Active infections or serious general medical conditions

         24. Patients with previous malignancies should only be permitted if they have been in a
             continued state of &quot;no evidence of disease&quot; for at least 5 years with the exception of
             adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS) of
             the breast, and basal cell/squamous cell skin cancer

         25. Known allergy to treatment medication or its excipients and/or to the contrast medium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Andtbacka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, SC</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Melanoma Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Centers</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>February 7, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>CALM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from medical clinics from 27-Dec-2011 to 29-Jul-2015 (last subject enrolled in VLA-008).</recruitment_details>
      <pre_assignment_details>Subjects were screened for and excluded from the study if they had pre-existing antibodies to CVA21.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CVA21</title>
          <description>CVA21 monotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CVA21</title>
          <description>CVA21 monotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="14.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.7" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.16" spread="21.869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months</title>
        <description>To assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>CVA21</title>
            <description>CVA21 monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months</title>
          <description>To assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months.</description>
          <population>ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" lower_limit="26.0" upper_limit="52.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Durable Response Rate</title>
        <description>Per Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI or calipers: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Durable Response Rate (DRR) = CR + PR.</description>
        <time_frame>6 months or more</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>CVA21</title>
            <description>CVA21 monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Durable Response Rate</title>
          <description>Per Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI or calipers: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Durable Response Rate (DRR) = CR + PR.</description>
          <population>ITT Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Listed SAEs and AEs are irrespective of treatment relationship. No SAEs reported were attributable to CVA21. No SUSARs were reported for the VLA-007/008 study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CVA21</title>
          <description>CVA21 monotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>motor dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>iron deficiency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="33" subjects_affected="23" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>influenza like illness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site discharge</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" events="49" subjects_affected="18" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hyperhidrosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark Grose</name_or_title>
      <organization>Viralytics</organization>
      <phone>1 647 821 7673</phone>
      <email>Mark.Grose@Viralytics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

